Last reviewed 2026-05-14 · How we verify

SIIL Live Attenuated Influenza Vaccine

SIIL Live Attenuated Influenza Vaccine works by exposing the body to a weakened form of the influenza virus to stimulate an immune response.

SIIL Live Attenuated Influenza Vaccine works by exposing the body to a weakened form of the influenza virus to stimulate an immune response. Used for Influenza prevention.

At a glance

Mechanism of action

This vaccine contains live, attenuated influenza viruses that are not capable of causing disease but can still trigger an immune response, providing protection against future infections. The immune system recognizes the weakened viruses as foreign and mounts a response, producing antibodies and immune cells that can recognize and fight the virus. This immune response helps to protect against future infections with the same or similar strains of the influenza virus.

Approved indications

• Influenza prevention

Common side effects

• Injection site pain
• Fatigue
• Headache

Key clinical trials

• A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh (PHASE3)
• Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal (PHASE3)
• Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• SIIL Live Attenuated Influenza Vaccine CI brief — competitive landscape report
• SIIL Live Attenuated Influenza Vaccine updates RSS · CI watch RSS
• PATH portfolio CI